跳至主要内容
临床试验/NCT07684131
NCT07684131招募中不适用

AN OBSERVATORY FOR PATIENTS AGED 18 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR::ABL1+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND TREATED WITH THE COMBINATION OF BCR::ABL1 INHIBITORS AND CHEMOTHERAPY AND/OR CORTICOSTEROIDS AND/OR A MONOCLONAL ANTIBODY.

Versailles Hospital23 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年1月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
23
主要终点
Overall survival by 12 months

研究概览

简要总结

An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients ≥ 18 years
  • Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia
  • Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody

排除标准

  • Patients deceded and having previously refused data collection
  • Not included in a prospective clinical trial

结局指标

主要结局

Overall survival by 12 months

时间窗: 12 months

次要结局

  • Death in complete remission(36 months)
  • the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood(36 months)
  • the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood(36 months)
  • Event free survival(36 months)
  • Relapse free survival(36 months)
  • the incidence ofBCR..ABL1 TK mutations(36 months)
  • treatment tolerance(36 months)
  • Death during induction(2 months)
  • overal survival by 36 months(36 months)
  • proportion of complete remission(36 months)

研究者

发起方
Versailles Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Philippe ROUSSELOT

Professor

Versailles Hospital

研究点 (23)

Loading locations...

相似试验